Table 1.
Characteristics of included studies.
| Source | Freynhofer et al. (27) | Tscharre et al. (26) | Cesari et al. (29) | López-Jiménez et al. (28) | Perl et al. (30) | Ibrahim et al. (31) |
|---|---|---|---|---|---|---|
| Country | Austria | Austria | Italy | Spain | Israel | USA |
| Type of cases | Post-PCI | Post-PCI | Post-PCI | ACS | SCAD with DM | CAD |
| Participants (n) | 486 | 477 | 229 | 251 | 104 | 89 |
| Laboratory parameter | IPF% | IPC | IPF% | IPF% | IPF% | IPC |
| Methodologies of RPs | Sysmex XE-2100 | Sysmex XE-2100 | Sysmex XE-2100 | Sysmex XE-2100 | Sysmex XE-2100 | Sysmex XE-2100 |
| Measuring time | 6–24 h after PCI | 6–24 h after PCI | 24–48 h after PCI | In the morning of the first day of hospitalization | N/A | Within 72 h of admission to the hospital |
| Median of follow-up | 190 days | 5.8 years | 1 years | In-hospital admission | 2 years | 31 months |
| Total CVEs (n) | 86 | 110 | 22 | 31 | 15 | 30 |
| Reported outcomes of interest | Death, MI, RVA, CVA | Death, MI, CVA | Death | Death | MI, RVA, CVA | Death, MI, RVA |
| RPs in CVEs | 4% [2.9–5.4] | N/A | 3.7% [2.4–5.0] | 6.60% [4.20–10.80] | 4.57% | 5.3% [4.3–6.4] |
| RPs in non-CVEs | 3.3% [2.4–4.7] | N/A | 2.8% [1.9–4.1] | 4.80% [3.10–6.95] | 2.53% | 3.7% [3.0–5.1] |
| P-value | 0.013 | N/A | 0.05 | 0.002 | <0.001 | 0.007 |
RPs, reticulated platelets; CAD, coronary artery disease; CVE, cardiovascular events; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; DM, diabetes mellitus; 95% CI, 95% confidence interval; N/A, not applicable; IPF%, immature platelet fraction; IPC, immature platelet count; MI, myocardial infarction; CVA, cerebrovascular accidents; RVA, revascularization.